Core Viewpoint - Stryker Corporation is a leading medical technology company set to announce its fiscal third-quarter earnings for 2025, with analysts expecting a positive earnings report and growth in EPS over the coming years [1][2][3]. Financial Performance - Analysts anticipate Stryker to report a profit of $3.14 per share for Q3 2025, reflecting a 9.4% increase from $2.87 per share in the same quarter last year [2]. - For the full fiscal year 2025, EPS is expected to be $13.50, a 10.8% increase from $12.19 in fiscal 2024, with further growth projected to $14.95 in fiscal 2026, representing a year-over-year rise of 10.7% [3]. Stock Performance - Stryker's stock has underperformed compared to the S&P 500 Index, which gained 13.5% over the past 52 weeks, while Stryker shares only increased by 2.2% during the same period [4]. - The stock also lagged behind the Health Care Select Sector SPDR Fund, which experienced a 7.2% decline [4]. Competitive Landscape - The company's underperformance is attributed to increased competition from Zimmer Biomet, Johnson & Johnson, and Medtronic, particularly in the robotic orthopedics segment, along with macroeconomic pressures such as inflation and wage pressures affecting margins [5]. Analyst Sentiment - The consensus among analysts is moderately bullish, with a "Moderate Buy" rating overall. Out of 28 analysts, 18 recommend a "Strong Buy," 2 suggest a "Moderate Buy," and 8 advise a "Hold" [7]. - The average analyst price target for Stryker is $434.48, indicating a potential upside of 17.7% from current levels [7].